David A. Siegel Theravance Biopharma, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 200,300 shares of TBPH stock, worth $3.48 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
200,300
Previous 29,100
588.32%
Holding current value
$3.48 Million
Previous $320,000
813.75%
% of portfolio
0.01%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding TBPH
# of Institutions
171Shares Held
50.5MCall Options Held
36.5KPut Options Held
147K-
Madison Avenue Partners, LP New York, NY9.51MShares$165 Million12.7% of portfolio
-
Weiss Asset Management LP Boston, MA7.46MShares$130 Million2.09% of portfolio
-
Newtyn Management, LLC New York, NY4.95MShares$86.1 Million12.08% of portfolio
-
Black Rock Inc. New York, NY3.78MShares$65.7 Million0.0% of portfolio
-
Irenic Capital Management LP New York, NY2.76MShares$48 Million4.22% of portfolio
About Theravance Biopharma, Inc.
- Ticker TBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,782,400
- Market Cap $1.16B
- Description
- Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...